Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803. - Wikidata - awgldk - TriplyDB

Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803.

Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803.

http://www.wikidata.org/entity/Q37412294

about

Children's Oncology Group's 2013 blueprint for research: Soft tissue sarcomas The novel tubulin polymerization inhibitor MHPT exhibits selective anti-tumor activity against rhabdomyosarcoma in vitro and in vivo Embryonic signaling pathways and rhabdomyosarcoma: contributions to cancer development and opportunities for therapeutic targeting Patterns of chemotherapy-induced toxicities in younger children and adolescents with rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma Committee Rhabdomyosarcoma: review of the Children's Oncology Group (COG) Soft-Tissue Sarcoma Committee experience and rationale for current COG studies Rhabdomyosarcoma in adolescent and young adult patients: current perspectives.Local failure in parameningeal rhabdomyosarcoma correlates with poor response to induction chemotherapy.Pediatric Rhabdomyosarcoma.Generation of novel patient-derived CIC- DUX4 sarcoma xenografts and cell lines.What is new in the biology and treatment of pediatric rhabdomyosarcoma?Undifferentiated sarcoma of the liver: a single institution experience using a uniform treatment approach.Early treatment failure in intermediate-risk rhabdomyosarcoma: results from IRS-IV and D9803--a report from the Children's Oncology Group.Randomized phase II window trial of two schedules of irinotecan with vincristine in patients with first relapse or progression of rhabdomyosarcoma: a report from the Children's Oncology Group.Age-related toxicity in patients with rhabdomyosarcoma: a report from the children's oncology group.Preliminary results of a phase II trial of proton radiotherapy for pediatric rhabdomyosarcoma.Histology, Fusion Status, and Outcome in Alveolar Rhabdomyosarcoma With Low-Risk Clinical Features: A Report From the Children's Oncology Group.A dosimetric comparison of proton and intensity modulated radiation therapy in pediatric rhabdomyosarcoma patients enrolled on a prospective phase II proton study.Tumor volume and patient weight as predictors of outcome in children with intermediate risk rhabdomyosarcoma: a report from the Children's Oncology Group.GLI inhibitor GANT-61 diminishes embryonal and alveolar rhabdomyosarcoma growth by inhibiting Shh/AKT-mTOR axis Treatment results for patients with localized, completely resected (Group I) alveolar rhabdomyosarcoma on Intergroup Rhabdomyosarcoma Study Group (IRSG) protocols III and IV, 1984-1997: a report from the Children's Oncology Group Rhabdomyosarcoma in infants younger than 1 year: a report from the Children's Oncology Group.Effect of radiotherapy techniques (IMRT vs. 3D-CRT) on outcome in patients with intermediate-risk rhabdomyosarcoma enrolled in COG D9803--a report from the Children's Oncology Group.Rhabdomyosarcoma of the head and neck in children Delayed primary excision with subsequent modification of radiotherapy dose for intermediate-risk rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma Committee.Proton radiotherapy for parameningeal rhabdomyosarcoma: clinical outcomes and late effects.The effect of radiation timing on patients with high-risk features of parameningeal rhabdomyosarcoma: an analysis of IRS-IV and D9803.Trial watch: Chemotherapy with immunogenic cell death inducers Clinical Application of Prognostic Gene Expression Signature in Fusion Gene-Negative Rhabdomyosarcoma: A Report from the Children's Oncology Group Dense pattern of embryonal rhabdomyosarcoma, a lesion easily confused with alveolar rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: a children's oncology group report.Local control and outcome in children with localized vaginal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma committee of the Children's Oncology Group.A Patient-Derived Xenograft Model of Parameningeal Embryonal Rhabdomyosarcoma for Preclinical Studies.Two Cases of Adolescents with Paratesticular Rhabdomyosarcoma Inadequately Treated: The Problem of Referral.From fighting depression to conquering tumors: a novel tricyclic thiazepine compound as a tubulin polymerization inhibitor Outcome of Rhabdomyosarcoma in First Year of Life: Children's Cancer Hospital 57357 Egypt.Histologic and clinical characteristics can guide staging evaluations for children and adolescents with rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma Committee.Prognostic Factors for Outcome in Localized Extremity Rhabdomyosarcoma. Pooled Analysis from Four International Cooperative Groups.Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.Parameningeal rhabdomyosarcoma in pediatric age: results of a pooled analysis from North American and European cooperative groups.Local Control for Intermediate-Risk Rhabdomyosarcoma: Results From D9803 According to Histology, Group, Site, and Size: A Report From the Children's Oncology Group

P2860

Q26825000-AB662352-CFD9-4A5C-BEA8-DF0D749ED7D4 Q28545041-2D1ABFBB-B159-44E6-A5C8-3FBA9DC4AC0C Q30426842-02974DC5-9FBB-4B8E-95FB-F03762656DB7 Q33396263-F8C85094-0C3D-46E4-9864-96AD681648E1 Q33559468-9E069C75-09E4-4019-B9B8-402CB6F9E7E4 Q33800135-D3E1C28F-9FE0-4CE5-81E3-88C8C84AD579 Q33821612-B415C4ED-B081-4A67-B520-7192CF57B912 Q33842070-88B8EABB-905D-49C6-9B25-8A8DE7E012D3 Q33875284-BF537D64-F2BA-4966-8288-5B6F1495CD04 Q33895506-60A65DB2-1DAF-412D-9920-DCBA5231A239 Q34040069-D5DFF446-8964-4AEC-862D-9599070A76EC Q34193980-4B3276EE-DF91-4686-9603-3629AE0D75BD Q34281235-A4018A71-4E8E-4C5A-8F6C-D98BFFB1AC35 Q34381149-A06DA225-1C13-4B5F-BA3F-AD7EA98B700F Q34484192-CF1C9439-497C-4253-947D-351B37E70405 Q34508636-49836F52-5270-414A-BE14-774BD26C5B3C Q34984155-D02E41DE-4EEC-4878-96BF-F377D8179C5D Q35051029-39F16CC8-AEE2-4124-B46D-5CF99CAB05A1 Q35067950-DADDAA04-3ACC-44FE-8BF6-905906805675 Q35084182-E9441922-23DD-47A8-A7E7-F5FDC284F887 Q35119012-4B725BDA-A73F-4F6C-A78E-1AD3268BC7D1 Q35161100-EAFADE7B-2B45-4DB6-B978-1334EB1FB9BA Q35648994-775599BF-3B18-4F4F-BC39-DE19FA1D2FCD Q35760674-E7B21CF3-DD71-4DEA-895E-18088EC9C937 Q35792061-2BFF2FE6-917C-4AB9-B43D-EE49257CF279 Q35914632-4D0A0EBB-98D8-4AC2-BA2E-6D48746DAD01 Q36038456-30A046E2-ED7A-4CD8-B38A-8012EAA056C3 Q36175120-A8139F9A-39C1-45B0-8299-EF0141D8D839 Q36219115-D0E4823E-CA94-4B0F-AB82-E1A923793BD5 Q36283044-737DB0BA-E471-40B8-AEC9-CF9B0D2AD6D9 Q36284400-66A2BD6F-B075-4043-AD8D-9CFE4930DD16 Q36367000-E52E5E4C-4E68-4B9F-A37E-2D8CD49B5067 Q36753647-2A42F70B-F760-469E-8236-91B834CF5F42 Q36775000-8C5FB8E4-F0AD-44CE-B495-330888AF2D63 Q37101239-660025C3-BD53-44D9-B5BE-53BF237613F4 Q37132373-360FD0B1-6FA9-4C8B-9F57-F402634F9D2F Q37212341-0AE8BE25-08F5-4734-847B-383B5362F9F5 Q37350775-DA035DE6-0156-405A-9AE6-A7BA8ADE9660 Q37404111-7CE21880-6E19-45C6-AECB-93F23E894680 Q37489203-9CE163E5-B22F-4B04-B1CF-3E9F645DAE05

P2860

Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803.

http://www.wikidata.org/entity/Q37412294

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 21 September 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Vincristine, actinomycin, and ...... 's oncology group study D9803.

@en

Vincristine, actinomycin, and ...... 's oncology group study D9803.

@nl

type

label

Vincristine, actinomycin, and ...... 's oncology group study D9803.

@en

Vincristine, actinomycin, and ...... 's oncology group study D9803.

@nl

prefLabel

Vincristine, actinomycin, and ...... 's oncology group study D9803.

@en

Vincristine, actinomycin, and ...... 's oncology group study D9803.

@nl

P1433

Q37412294-2E559F5B-734C-4715-8C3E-A0A4B79BF674

P1476

Q37412294-1A05959F-6CE7-450F-AC22-FB6C7BB19F4D

P2093

Q37412294-0B3FE7E2-88C6-47EC-A189-D8312B560A93

Q37412294-2D80265C-0B59-4087-A390-A49586BFDC6A

Q37412294-44EDD1B4-89B9-499B-925B-3DC566D3F8B4

Q37412294-4EFF397D-3455-4F0F-95B0-2E04AC051EB9

Q37412294-5460D4A0-45FD-4B60-8460-DF78CC79DCF5

Q37412294-548B029C-97B2-47FF-A75A-1A402F1DC833

Q37412294-8D56E24D-A933-49B1-9C3C-113559819D52

Q37412294-9065487E-EDDF-482E-BFEF-2ABB0076C1EC

Q37412294-920737CD-F4AF-4A6E-9114-E63FA9A781CB

Q37412294-9F370F48-20BB-4B13-89AE-4E01DA97E49E

P2860

Q37412294-11256089-A265-46BE-A7A0-6E0D972DCFF3

Q37412294-22D93B27-A142-4D6A-8434-178DEBA3E3C6

Q37412294-36A7E4DE-A5CE-43FE-ABD9-94AF4E0C6340

Q37412294-392B662F-A59B-40E7-97CA-212E2396BD2D

Q37412294-65B8882A-E71A-43B2-B3BB-34AA8B747E5D

Q37412294-7554A5C7-2373-4FEF-A5AB-70F4C9A3CFA5

Q37412294-8E728D6A-7307-4B6B-B4A9-08A2CBCED982

Q37412294-997533E8-AF0C-429D-94D0-804C8CF1078D

Q37412294-A83B8FF4-D37C-44AC-8D49-CD7669284DEF

Q37412294-ACADD58E-F0DE-48C1-B4FC-910863675135

P304

Q37412294-9302BF8C-D414-4754-A86D-F6E2675C4069

P31

Q37412294-FD5E11B2-6A0F-44E8-8782-332F62673E34

P356

Q37412294-63538732-CE11-49B1-BA46-11EF0A6F785A

P407

Q37412294-9F0644CE-D5E6-4886-8835-48FDD454C8D6

P433

Q37412294-93928B1A-B97E-4364-949B-A3336B17AFAF

P478

Q37412294-CE8B16BB-7894-4427-A881-7CFBE0198986

P577

Q37412294-EFCBD0A9-553F-4650-8624-EFFBC64FFA26

P698

Q37412294-A8E3B1B2-DF75-4164-B55B-FADB99DCC5F5

P932

Q37412294-DEC7B8BD-EED4-4986-AC85-6C74BC5B031D

P356

JCO.2009.22.3768

P1433

Journal of Clinical Oncology

P1476

Vincristine, actinomycin, and ...... 's oncology group study D9803.

@en

P2093

Andrea A Hayes-Jordan

http://www.w3.org/2001/XMLSchema#string

Carola A S Arndt

http://www.w3.org/2001/XMLSchema#string

Charles N Paidas

http://www.w3.org/2001/XMLSchema#string

David A Rodeberg

http://www.w3.org/2001/XMLSchema#string

David M Parham

http://www.w3.org/2001/XMLSchema#string

Douglas S Hawkins

http://www.w3.org/2001/XMLSchema#string

James R Anderson

http://www.w3.org/2001/XMLSchema#string

John C Breneman

http://www.w3.org/2001/XMLSchema#string

Julie A Stoner

http://www.w3.org/2001/XMLSchema#string

Lisa A Teot

http://www.w3.org/2001/XMLSchema#string

P2860

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples

Up-front window trial of topotecan in previously untreated children and adolescents with metastatic rhabdomyosarcoma: an intergroup rhabdomyosarcoma study.

Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease.

The Intergroup Rhabdomyosarcoma Study-I. A final report.

Biology and therapy of pediatric rhabdomyosarcoma.

The Intergroup Rhabdomyosarcoma Study-II.

Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V.

Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from th

Venoocclusive disease of the liver after chemotherapy with vincristine, actinomycin D, and cyclophosphamide for the treatment of rhabdomyosarcoma. A report of the Intergroup Rhabdomyosarcoma Study Group. Childrens Cancer Group, the Pediatric Oncolog

Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhi

P304

5182-5188

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2009.22.3768

http://www.w3.org/2001/XMLSchema#string

P407

P433

31

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P577

2009-09-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19770373

http://www.w3.org/2001/XMLSchema#string

P932

2773476

http://www.w3.org/2001/XMLSchema#string